<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mediwound Ltd — News on 6ix</title>
<link>https://6ix.com/company/mediwound-ltd</link>
<description>Latest news and press releases for Mediwound Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mediwound-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835974b78dffbe2df104ecb.webp</url>
<title>Mediwound Ltd</title>
<link>https://6ix.com/company/mediwound-ltd</link>
</image>
<item>
<title>MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-reports-barda-contract-award-to-vericel-for-nexobridr-valued-at-up-to-dollar197-million</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-reports-barda-contract-award-to-vericel-for-nexobridr-valued-at-up-to-dollar197-million</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a</description>
</item>
<item>
<title>MediWound Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-reports-fourth-quarter-and-full-year-2025-financial-results-7</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-reports-fourth-quarter-and-full-year-2025-financial-results-7</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>EscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million</description>
</item>
<item>
<title>MediWound Files Annual Report on Form 20-F</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-files-annual-report-on-form-20-f-19</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-files-annual-report-on-form-20-f-19</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic</description>
</item>
<item>
<title>MediWound to Report Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-to-report-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-to-report-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026. Following the release, MediWound’s management wil</description>
</item>
<item>
<title>MediWound to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-to-present-at-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-to-present-at-upcoming-investor-conferences</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Time: 10:40 a.m. ET Location: Virtual Webcast: Available via conference website TD Cowen 46th Annual Healt</description>
</item>
<item>
<title>MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-provides-corporate-financial-outlook-120000318</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-provides-corporate-financial-outlook-120000318</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to diabetic foot ulcers (DFUs) and pressure ulcers (PUs) anticipated in 2026 Expanded NexoBrid® manufacturing facility fully operational; regulatory approvals targeted for 2026 $17 million in 2025 revenue; financial guidance updated to $24–26 mi</description>
</item>
<item>
<title>MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-reports-clinical-data-demonstrating-120000474</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-reports-clinical-data-demonstrating-120000474</guid>
<pubDate>Wed, 10 Dec 2025 12:00:00 GMT</pubDate>
<description>MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid® removes embedded particles in friction and blast wounds, reducing pigmented wound surface by >90% Traumatic tattoos form when dirt, metal, or explosive residue becomes permanently embedded in the skin; findings support further evaluation in acute trauma settings YAVNE, Israel, December 10, 2025 -- MediWound Ltd. (Na</description>
</item>
<item>
<title>MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-reports-third-quarter-2025-120000024</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-reports-third-quarter-2025-120000024</guid>
<pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
<description>Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid® Facility; Full Operational Capacity Expected by Year-End 2025 Balance Sheet Strengthened with $30 Million Equity Financing Third Quarter 2025 Revenue of $5.4 Million, Up 23% Year-over-Year Conference Call Today, November 20, 2025, at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-gene</description>
</item>
<item>
<title>MediWound to Report Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-report-third-quarter-2025-123000019</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-report-third-quarter-2025-123000019</guid>
<pubDate>Wed, 05 Nov 2025 12:30:00 GMT</pubDate>
<description>MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2025 on Thursday, November 20, 2025. Following the release, the Company’s management will hos</description>
</item>
<item>
<title>MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-successfully-completes-commissioning-expanded-130000424</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-successfully-completes-commissioning-expanded-130000424</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® Newly commissioned facility marks a significant development toward a sixfold production capacity increase ahead of full operational readiness by year-end 2025 YAVNE, Israel, November 3, 2025 – MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the successful completion of the commissioning process for its expanded GMP manufac</description>
</item>
<item>
<title>MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-announces-30-million-registered-123700741</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-announces-30-million-registered-123700741</guid>
<pubDate>Mon, 29 Sep 2025 12:37:00 GMT</pubDate>
<description>MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into a definitive securities purchase agreement led by a prominent U.S.-based mutual fund and other healthcare-focused investors for the sale and purchase of 1,734,105 ordinary shares of the Company, par value NIS 0.07 per sh</description>
</item>
<item>
<title>MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-expands-global-reach-marketing-113000624</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-expands-global-reach-marketing-113000624</guid>
<pubDate>Thu, 25 Sep 2025 11:30:00 GMT</pubDate>
<description>MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion YAVNE, Israel, September 25, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid®, the Company’s in</description>
</item>
<item>
<title>MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-nexobrid-highlighted-36-scientific-113000377</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-nexobrid-highlighted-36-scientific-113000377</guid>
<pubDate>Tue, 02 Sep 2025 11:30:00 GMT</pubDate>
<description>MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin, Germany. NexoBrid®, the company’s enzymatic burn debridement therapy, will be featured in 36 scientific</description>
</item>
<item>
<title>MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-present-h-c-wainwright-113000128</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-present-h-c-wainwright-113000128</guid>
<pubDate>Wed, 20 Aug 2025 11:30:00 GMT</pubDate>
<description>YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference. A live webcast of the event will be accessible both here and on MediW</description>
</item>
<item>
<title>MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-reports-second-quarter-2025-110000701</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-reports-second-quarter-2025-110000701</guid>
<pubDate>Thu, 14 Aug 2025 11:00:00 GMT</pubDate>
<description>VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next</description>
</item>
<item>
<title>MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-announces-escharex-phase-ii-124500500</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-announces-escharex-phase-ii-124500500</guid>
<pubDate>Wed, 13 Aug 2025 12:45:00 GMT</pubDate>
<description>MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wound bed preparation as a critical step in the healing process YAVNE, Israel, August 13, 2025 (GLOBE NEWSWIRE) – MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of “The Co</description>
</item>
<item>
<title>MediWound to Report Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-report-second-quarter-2025-113000744</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-report-second-quarter-2025-113000744</guid>
<pubDate>Mon, 04 Aug 2025 11:30:00 GMT</pubDate>
<description>MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound’s management will host a conference call and liv</description>
</item>
<item>
<title>MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-reports-first-quarter-2025-110000266</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-reports-first-quarter-2025-110000266</guid>
<pubDate>Wed, 21 May 2025 11:00:00 GMT</pubDate>
<description>VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financi</description>
</item>
<item>
<title>MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-announces-publication-phase-ii-113000884</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-announces-publication-phase-ii-113000884</guid>
<pubDate>Tue, 13 May 2025 11:30:00 GMT</pubDate>
<description>Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company’s Phase II ChronEx clinical trial in patients with venous le</description>
</item>
<item>
<title>MediWound to Report First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/mediwound-ltd/news/mediwound-report-first-quarter-2025-120000111</link>
<guid isPermaLink="true">https://6ix.com/company/mediwound-ltd/news/mediwound-report-first-quarter-2025-120000111</guid>
<pubDate>Mon, 05 May 2025 12:00:00 GMT</pubDate>
<description>Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern TimeYAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss</description>
</item>
</channel>
</rss>